Our mission is to develop disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases to address the unmet medical need.

Herantis Pharma logo

Find us on LinkedIn

 

  • Highlight

    Notice to Convene Herantis Pharma Plc’s Annual General Meeting of Shareholders 30 March, 2026

  • Highlight

    Herantis Pharma Plc Annual report 2025

  • Highlight

    FY 2025 report webcast

  • Highlight

    Herantis Pharma Phase 1b biomarker data webcast

  • Highlight

    Topline Phase 1b data webcast

  • Highlight

    Edison TV interview with Herantis CEO, Antti Vuolanto

Latest news and releases